Phase 4 N=701 Treatment of Smoking Lapses and Relapses
Smoking Cessation
Primary: Point-prevalent Abstinence at 4 Months — 90; 59 Participants — p=0.48
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=62 The Effect of Varenicline (Chantix) and Bupropion (Zyban) on Smoking Lapse Behavior
Smoking Lapse Behavior
Primary: Latency to Initiate Ad-lib Smoking Session — 38.138; 39.416; 19.249 minutes
N/A N=12 Effect of Smoking Exposure on Smoking Relapse Following Brief Abstinence - 2
Tobacco Use Disorder
Primary: Cigarette Choice After 3 Day Abstinence — 2.50; 3.67 number of cigarette choices (0-6)
Phase 3 N=216 Maintaining Nonsmoking
Nicotine Dependence
Primary: Number of Participants With Reported 7-day Point Prevalence Abstinence at Week 12 — 22; 20; 29; 20 Participants
Phase 4 N=104 Relapse Prevention With Varenicline
Recurrence · Smoking Cessation · Substance-Related Disorders
Primary: Days to Relapse — 9.1; 16.4 days
Phase 2 N=30 The Effect of Naltrexone and Varenicline on Alcohol-Mediated Smoking Lapse
Smoking
Primary: Latency to Initiate Ad-lib Smoking Session — 28.134; 45.861; 21.737 minutes
Phase 2 N=17 Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?
Smoking
Primary: Latency — 24.56; 26.64 minutes
Phase 2 N=100 Modeling Stress-precipitated Smoking Behavior for Medication Development
Smoking
Primary: Latency to Initiate Ad-lib Smoking Session — 31.55; 30.31 minutes
N/A N=369 Cessation in Non-Daily Smokers
Smoking
Primary: Smoking Cessation, Continuous 6-month Abstinence — 13; 10 Participants — p=0.46
N/A N=93 Evaluation of Learning-Theory-Based Smoking Cessation Strategies
Nicotine Dependence
Primary: 4-week Abstinence — 15; 17; 29; 20 participants
N/A N=136 Relapse Prevention Through Social Networking Groups
Smoking
Primary: Self Reported Relapse Rate at 2 Months — 3; 10; 13 participants — p=0.033
Phase 4 N=517 Identifying Treatments to Motivate Smokers to Quit
Smoking · Smoking Cessation · Motivation
Primary: Percent Change in Cigarettes Smoked Per Day (CPD) — 38.7; 38.9; 37.4; 40.2 Percent Change in cigarettes per day — p=.98
N/A N=34 Strengthening Instrumental Extinction to Prevent Smoking Relapse (VLNCCue)
Cigarette Smoking
Primary: Change in Fagerstrom Test of Nicotine Dependence Score — .67; 1.33 score on a scale — p=0.39
N/A N=5 Effects of Smoking State on Decision Making
Behavior
Primary: Effort Based Decision Making — 29.5; 18.3 high effort selections
N/A N=149 tDCS Effects on Resisting Smoking: Dose Ranging Study
Nicotine Addiction
Primary: Resisting Smoking - Time to First Cigarette in the Resist Smoking Paradigm — 60.3; 63.4; 63.2 minutes — p=0.94
N/A N=239 Increasing Contingency Management Success in Smoking Cessation
Smoking
Primary: Breath Carbon Monoxide Levels Indicating Smoking Abstinence During the Study, i.e., the Number of Breath Samples With Carbon Monoxide (CO) Levels Less Than 3 Parts Per…
Phase 2 N=184 Behavioral Activation Intervention for Smoking Cessation in Smokers With Depressive Symptoms
Cigarette Smoking
Primary: Number of Participants Smoking-Abstinent for 7 Days, 52 Weeks Post Quit Date — 26; 19 Participants
N/A N=116 Coping Skills Treatment for Smoking Cessation
Nicotine Dependence
Primary: Number of Participants With Biochemically Verified Smoking Abstinence — 11; 12 Participants
N/A N=34 Youth Smoking Cessation: Therapy +/- "The Patch"
Smoking
Primary: Acceptance of Nicotine Replacement Therapy — 26 participants
N/A N=241 Cognition and Smoking Relapse (HCS)
Smoking Cessation
Primary: Cognitive Function — 0.125; -.093; -.059; -.008 z-score
Phase 2 N=746 Gradual vs. Abrupt Cessation Treatment for Smoking
Smoking Cessation
Primary: Number of Participants With Prolonged Abstinence Through 6 Months Verified by Carbon Monoxide Measurement — 12; 20; 7 participants — p=0.30
Phase 2 N=24 Effects of Semaglutide on Nicotine Intake
Tobacco Use Disorder · Nicotine Addiction
Primary: Change in Nicotine Self-Administration — -0.8; -0.5 Number of cigarettes
N/A N=18 Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study
Copd · Smoking Cessation · Nicotine Dependence
Primary: Number of Participants Who Achieved 24-hour Smoking Abstinence at End-of-treatment — 1; 1; 2 Participants
Phase 4 N=820 Smokers' Health Project: Self-Determination and Maintaining Tobacco Abstinence
Tobacco Use Disorder
Primary: 12 Month Prolonged Abstinence From Tobacco Measured at 12 Months From Completion of Intervention. — 169; 321; 318 participants
Phase 1 N=58 Persistence-Targeted Smoking Cessation
Tobacco Use Disorder
Primary: 7-day Point Prevalence Abstinence — 4; 1 participants
Phase 4 N=29 Measuring Smoking Behaviors While Using Varenicline
Nicotine Dependence
Primary: Smoking Topography: Total Puff Volume — 523.4; 684.6 milliliters
N/A N=139 Cigarette Smoking Among Young Adults
Cigarette Smoking · Smoking Behaviors
Primary: Puff Topography — 1108; 1045.2; 1084.6 mL
N/A N=433 Take a Break (TAB): mHealth-assisted Skills Building Challenge for Unmotivated Smokers
Smoking Cessation
Primary: Time to First Quit Attempt — 0.89; 1.48 days — p=0.02
Phase 2 N=35 Does Doxazosin Attenuate Stress-induced Smoking and Improve Clinical Outcomes?
Smoking
Primary: Latency (Min) to Initiate Ad-lib Smoking Session — 11.304; 32.128; 27.557; 23.474 minutes
N/A N=234 Assessment of a Teachable Moment for Smoking Cessation
Nicotine Dependence
Primary: Accrual Rate (Eligibility Visit) — 85; 72 participants